HZO:NYSEMarineMax, Inc. (FL) Analysis
Data as of 2026-05-22 - not real-time
$34.20
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
MarineMax is trading above its short‑term moving averages, indicating that momentum remains on the upside. The 20‑day SMA sits above the 50‑day SMA, and the stock is also above the 200‑day SMA, reinforcing a bullish trend. RSI is comfortably above the neutral 50 mark, while the MACD line has crossed above its signal line, producing a bullish histogram. Volume has been rising, supporting the price advance. The price is holding near a key resistance level just below the recent 52‑week high. A nearby support zone provides a cushion should the rally falter.
Fundamentally, the company posted a loss per share in the latest quarter, and revenue fell short of expectations, reflecting softness in the boating market. Nevertheless, gross margins stayed strong and operating cash flow remains positive, underscoring the resilience of the business model. Forward earnings estimates have turned positive, and the DCF model suggests a fair value notably lower than the current market price, making the stock appear overvalued. The balance sheet is leveraged, with debt exceeding equity, which adds financial risk. Analyst consensus is a strong‑buy, but the market appears to price in optimism already. Given the mix of bullish technical signals and overvalued valuation, the stock sits at a crossroads between short‑term upside and longer‑term caution.
Fundamentally, the company posted a loss per share in the latest quarter, and revenue fell short of expectations, reflecting softness in the boating market. Nevertheless, gross margins stayed strong and operating cash flow remains positive, underscoring the resilience of the business model. Forward earnings estimates have turned positive, and the DCF model suggests a fair value notably lower than the current market price, making the stock appear overvalued. The balance sheet is leveraged, with debt exceeding equity, which adds financial risk. Analyst consensus is a strong‑buy, but the market appears to price in optimism already. Given the mix of bullish technical signals and overvalued valuation, the stock sits at a crossroads between short‑term upside and longer‑term caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bullish technical indicators (moving averages, MACD, RSI)
- Current price near resistance with limited upside
- Recent earnings miss on revenue
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong gross margins and positive operating cash flow
- Forward EPS turning positive
- Analyst consensus of strong‑buy supporting upside potential
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High leverage and debt‑to‑equity ratio
- Consumer‑cyclical exposure to discretionary boating demand
- Valuation gap suggesting limited long‑term upside
Key Metrics & Analysis
Financial Health
Revenue Growth-16.50%
Profit Margin-2.83%
P/E Ratio21.1
ROE-6.46%
ROA1.14%
Debt/Equity127.78
P/B Ratio0.8
Op. Cash Flow$218.7M
Free Cash Flow$126.6M
Technical Analysis
TrendBullish
RSI62.2
Support$27.50
Resistance$34.68
MA 20$31.54
MA 50$28.98
MA 200$26.82
MACDBullish
VolumeIncreasing
Fear & Greed Index91.5
Valuation
Fair Value$28.65
Target Price$35.29
Upside/Downside3.17%
GradeOvervalued
TypeBlend
Risk Assessment
Beta2.04
Volatility56.05%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.